Vaccines: Past, Present and Future

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2005 Apr 7

PMID 15812490

Citations 167

Authors

Stanley A Plotkin

Affiliations

Soon will be listed here.

Abstract

The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines.

Citing Articles

-Derived β-Glucan Capsules as a Delivery System for DNA Vaccines.

Pinho S, Invencao M, Silva A, Macedo L, Espinoza B, Leal L Vaccines (Basel). 2025; 12(12.

PMID: 39772088 PMC: 11728682. DOI: 10.3390/vaccines12121428.

Optimal vaccination policy to prevent endemicity: a stochastic model.

Foutel-Rodier F, Charpentier A, Guerin H J Math Biol. 2024; 90(1):10.

PMID: 39694893 PMC: 11655619. DOI: 10.1007/s00285-024-02171-z.

mRNA vaccine sequence and structure design and optimization: Advances and challenges.

Jin L, Zhou Y, Zhang S, Chen S J Biol Chem. 2024; 301(1):108015.

PMID: 39608721 PMC: 11728972. DOI: 10.1016/j.jbc.2024.108015.

Co-expression gene module analysis in response to attenuated cercaria vaccine reveals a critical role for NK cells in protection against Schistosoma mansoni.

Neto A, Vitoriano-Souza J, Khouri M, Favaro R, Wilson R, Leite L Parasit Vectors. 2024; 17(1):476.

PMID: 39563428 PMC: 11575109. DOI: 10.1186/s13071-024-06505-0.

Prophylactic and therapeutic vaccine development: advancements and challenges.

Weerarathna I, Doelakeh E, Kiwanuka L, Kumar P, Arora S Mol Biomed. 2024; 5(1):57.

PMID: 39527305 PMC: 11554974. DOI: 10.1186/s43556-024-00222-x.

References

Moingeon P, Haensler J, Lindberg A . Towards the rational design of Th1 adjuvants. Vaccine. 2001; 19(31):4363-72. DOI: 10.1016/s0264-410x(01)00193-1. View

Tacket C . Garden-variety vaccines: antigens derived from transgenic plants. Expert Rev Vaccines. 2004; 3(5):529-31. DOI: 10.1586/14760584.3.5.529. View

Sela M, Hilleman M . Therapeutic vaccines: realities of today and hopes for tomorrow. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14559. PMC: 522000. DOI: 10.1073/pnas.0405924101. View

Jones T, Allard F, Cyr S, Tran S, Plante M, Gauthier J . A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine. 2003; 21(25-26):3706-12. DOI: 10.1016/s0264-410x(03)00387-6. View

Levin M, Smith J, Kaufhold R, Barber D, Hayward A, Chan C . Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003; 188(9):1336-44. DOI: 10.1086/379048. View

Dhiman N, Bonilla R, OKane D, Poland G . Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine. 2001; 20(1-2):22-30. DOI: 10.1016/s0264-410x(01)00319-x. View

Excler J, Plotkin S . The prime-boost concept applied to HIV preventive vaccines. AIDS. 1997; 11 Suppl A:S127-37. View

Stevceva L, Strober W . Mucosal HIV vaccines: where are we now?. Curr HIV Res. 2004; 2(1):1-10. DOI: 10.2174/1570162043485004. View

Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth M, Valent P . Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14677-82. PMC: 521981. DOI: 10.1073/pnas.0404735101. View

10.

Plotkin S . Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001; 20(1):63-75. DOI: 10.1097/00006454-200101000-00013. View

11.

Mikszta J, Alarcon J, Brittingham J, Sutter D, Pettis R, Harvey N . Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med. 2002; 8(4):415-9. DOI: 10.1038/nm0402-415. View

12.

Fattom A, Horwith G, Fuller S, Propst M, Naso R . Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine. 2004; 22(7):880-7. DOI: 10.1016/j.vaccine.2003.11.034. View

13.

Hoft D, Leonardi C, Milligan T, Nahass G, Kemp B, Cook S . Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination. Clin Infect Dis. 2000; 28(4):785-90. DOI: 10.1086/515201. View

14.

Rayner J, Dryga S, Kamrud K . Alphavirus vectors and vaccination. Rev Med Virol. 2002; 12(5):279-96. DOI: 10.1002/rmv.360. View

15.

Forsyth K, Campins-Marti M, Caro J, Cherry J, Greenberg D, Guiso N . New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis. 2004; 39(12):1802-9. DOI: 10.1086/426020. View

16.

Theiler M, Smith H . THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION. J Exp Med. 2009; 65(6):787-800. PMC: 2133527. DOI: 10.1084/jem.65.6.787. View

17.

Arvin A, Fast P, Myers M, Plotkin S, Rabinovich R . Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004; 39(2):233-9. DOI: 10.1086/421999. View

18.

Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K . Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004; 78(9):4761-75. PMC: 387722. DOI: 10.1128/jvi.78.9.4761-4775.2004. View

19.

Vandepapeliere P . Therapeutic vaccination against chronic viral infections. Lancet Infect Dis. 2002; 2(6):353-67. DOI: 10.1016/s1473-3099(02)00289-x. View

20.

Lewis J . Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14653-6. PMC: 521987. DOI: 10.1073/pnas.0404839101. View